10 Best Biotech and AI Stocks To Buy According To Quant Billionaire Jim Simons
Euclidean Capital is the family office of billionaire hedge fund manager James "Jim" Simons.
Ngm Biopharmaceuticals Inc (NGM)
Get Email AlertsHedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Point72 Asset Management Steve Cohen | 3,210,871 | $48,966 | -3% | 0.19% |
| 2. | Stepstone Group Jose Fernandez | 1,573,357 | $23,994 | 1.78% | |
| 3. | Biotechnology Value Fund / BVF Inc Mark Lampert | 955,000 | $14,564 | 0.58% | |
| 4. | Euclidean Capital Jim Simons | 746,674 | $11,387 | 6.61% | |
| 5. | EcoR1 Capital Oleg Nodelman | 541,108 | $8,252 | 0.25% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.20 | 2,067 | Large Shareholder, Director | 47,677 | 2022-05-18 | Filing | |
| $13.20 | 60,583 | Large Shareholder, Director | 1,397,044 | 2022-05-18 | Filing | |
| $13.42 | 2,939 | Large Shareholder, Director | 45,610 | 2022-05-17 | Filing | |
| $13.42 | 86,110 | Large Shareholder, Director | 1,336,461 | 2022-05-17 | Filing | |
| $13.20 | 2,067 | Large Shareholder, Director | 47,677 | 2022-05-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.60 | 15,000 | Officer, Director | 908,893 | 2021-12-07 | Filing | |
| $18.21 | 15,000 | Officer, Director | 854,449 | 2021-12-06 | Filing | |
| $20.02 | 15,000 | Officer, Director | 0 | 2021-11-18 | Filing | |
| $19.56 | 15,000 | Officer, Director | 869,449 | 2021-11-15 | Filing | |
| $19.89 | 15,000 | Officer, Director | 884,449 | 2021-11-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 22,012 | $335,683 | 0% | |
| 2. | 18,629 | $284,093 | 0% | |
| 3. | 16,245,817 | $247,749 | 45.93% | |
| 4. | 3,766,666 | $57,442 | 39.73% | |
| 5. | 3,014,475 | $45,971 | 0% |
News See All
Hedge Funds Are Crazy About NGM Biopharmaceuticals, Inc. (NGM)
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
Hedge Funds Are Piling Into NGM Biopharmaceuticals, Inc. (NGM)
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change their opinion towards a...
5 Pharmaceutical Stocks to Buy According to Jim Simons’ Euclidean Capital
Below is the list of 5 pharmaceutical stocks to buy according to Jim Simons’ Euclidean Capital.
5 Best Pharma and Biotech Stocks to Buy According to Jim Simons’ Euclidean Capital
In this article, we discuss the 5 best pharma and biotech stocks to buy according to Jim Simons' Euclidean Capital.
Were Hedge Funds Right About NGM Biopharmaceuticals, Inc. (NGM)?
In this article we will analyze whether NGM Biopharmaceuticals, Inc.
Is NGM A Good Stock To Buy Now?
In this article we will check out the progression of hedge fund sentiment towards NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) and determine whether it is a good investment right now.
Were Hedge Funds Right About Warming Up To NGM Biopharmaceuticals, Inc. (NGM)?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
NGM Biopharmaceuticals, Inc. (NGM): Were Hedge Funds Right About This Stock?
Will the new coronavirus cause a recession in US in the next 6 months? On February 27th, we put the probability at 75% and we predicted that the market will decline by at least 20% in (Recession is Imminent...
Hedge Fund and Insider Trading News: Mark Yusko, Ray Dalio, Christopher Hohn, Glenview Capital Management, Pool Corporation (POOL), Union Pacific Corporation (UNP), and More
Hedge fund manager Mark Yusko is telling investors to brace for a nearly once in a lifetime downturn.
Billionaire Hedge Funds
